Literature DB >> 32146220

Evaluation of Potential Systemic Adverse Events Related to Fluorescein Angiography in Pediatric Patients.

Ru-Ik Chee1, Mrinali P Gupta2, Nita G Valikodath3, Emily Cole3, Anton Orlin2, Tala Al-Khaled3, Irene Rusu2, Samir N Patel4, June Han5, Vivien Yap6, Karyn E Jonas3, Peter J Campbell7, Michael F Chiang7, R V Paul Chan8.   

Abstract

PURPOSE: To evaluate adverse events of fluorescein angiography (FA) in pediatric patients.
DESIGN: Single-institution retrospective chart review. PARTICIPANTS: Patients 0 to 18 years of age who underwent FA between January 2010 and December 2015 at a single institution in the United States.
METHODS: Pediatric patients who underwent FA by 3 surgeons were included in the study. Patients with fewer than 24 hours of documented follow-up were excluded. Significant adverse events within 24 hours of FA were evaluated. Detailed intraoperative and perioperative physiological parameters, including heart rate, blood pressure, oxygen saturation, and ventilation parameters, in inpatients undergoing simultaneous examination under anesthesia were reviewed. Peri-injection effects of FA were evaluated by 2-tailed paired t test comparison of mean 5-minute preinjection and 5-minute postinjection physiological data. MAIN OUTCOME MEASURES: Significant adverse events associated with FA.
RESULTS: One hundred fifteen patients with a total of 214 FA examinations were included. No significant adverse events were associated directly with FA. Comparison of mean 5-minute preinjection and postinjection physiologic parameters in 27 patients who underwent intravenous FA during EUA did not reveal significant changes associated with FA. A significant difference was found in average patient age between inpatient (2.5 years) and outpatient (10.7 years) FA (P < 0.00001). The youngest patients who underwent successful FA were 3.8 years old in the outpatient setting and 32 weeks' postmenstrual age in the inpatient setting. Patients younger than 3.8 years accounted for most (77.6%; n = 85) inpatient FA examinations. Excluding patients with a need or likely need for laser or surgery, the reasons for inpatient FA in patients older than 3.8 years included the lack of availability of outpatient ultra-widefield FA (UWFA) and more challenging situations in patients with developmental delay.
CONCLUSIONS: Fluorescein angiography was not found to be associated directly with systemic adverse events in pediatric patients in this study. Younger patients more commonly were found to require an inpatient FA, whereas older patients older than 4 years underwent outpatient UWFA.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 32146220      PMCID: PMC7880605          DOI: 10.1016/j.oret.2019.12.012

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  34 in total

1.  Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children.

Authors:  Michael P Blair; Michael J Shapiro; M Elizabeth Hartnett
Journal:  J AAPOS       Date:  2012-06       Impact factor: 1.220

2.  Recurrence of retinopathy of prematurity following bevacizumab monotherapy: is it only the tip of the iceberg?

Authors:  Kamiar Mireskandari; Gillian G W Adams; Nasrin N Tehrani
Journal:  JAMA Ophthalmol       Date:  2013-04       Impact factor: 7.389

3.  Retinal vasoproliferative tumors in ocular conditions of childhood.

Authors:  Jerry A Shields; David Reichstein; Arman Mashayekhi; Carol L Shields
Journal:  J AAPOS       Date:  2012-02       Impact factor: 1.220

4.  Fluorescein angiography in retrolental fibroplasia.

Authors:  J W Payne; A Patz
Journal:  Int Ophthalmol Clin       Date:  1977

5.  Probability of adverse events that have not yet occurred: a statistical reminder.

Authors:  E Eypasch; R Lefering; C K Kum; H Troidl
Journal:  BMJ       Date:  1995-09-02

6.  Adverse reactions to fluorescein angiography: A comprehensive review of the literature.

Authors:  Ilyse S Kornblau; Jaafar F El-Annan
Journal:  Surv Ophthalmol       Date:  2019-02-14       Impact factor: 6.048

7.  Influence of Fluorescein Angiography on the Diagnosis and Management of Retinopathy of Prematurity.

Authors:  Michael A Klufas; Samir N Patel; Michael C Ryan; Mrinali Patel Gupta; Karyn E Jonas; Susan Ostmo; Maria Ana Martinez-Castellanos; Audina M Berrocal; Michael F Chiang; R V Paul Chan
Journal:  Ophthalmology       Date:  2015-05-28       Impact factor: 12.079

8.  Adverse effects of fluorescein angiography in hypertensive and elderly patients.

Authors:  Fayyaz Musa; Wisam J Muen; Richard Hancock; David Clark
Journal:  Acta Ophthalmol Scand       Date:  2006-12

9.  Visual acuity of eyes after vitrectomy for retinopathy of prematurity: follow-up at 5 1/2 years. The Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors:  G E Quinn; V Dobson; C C Barr; B R Davis; E A Palmer; J Robertson; C G Summers; M T Trese; B Tung
Journal:  Ophthalmology       Date:  1996-04       Impact factor: 12.079

10.  Ultra-widefield fundus fluorescein angiography in pediatric retinal vascular diseases.

Authors:  Shreyas Temkar; Shorya V Azad; Rohan Chawla; Sourav Damodaran; Gaurav Garg; Harika Regani; Shaikh Nawazish; Nimmy Raj; Vatsalya Venkatraman
Journal:  Indian J Ophthalmol       Date:  2019-06       Impact factor: 1.848

View more
  1 in total

Review 1.  Imaging in Retinopathy of Prematurity.

Authors:  N Valikodath; E Cole; M F Chiang; J P Campbell; R V P Chan
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2019 Mar-Apr
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.